PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 :
A61K 31/235, 31/195

A1

(11) International Publication Number: WO 93/25201

(43) International Publication Date: 23 December 1993 (23.12.93)

(21) International Application Number: PCT/US93/05555

(22) International Filing Date: 10 June 1993 (10.06.93)

(30) Priority data:
07/898,295 15 June 1992 (15.06.92) US

(71)(72) Applicant and Inventor: BURZYNSKI, Stanislaw, R. [US/US]; 20 West Rivercrest, Houston, TX 77042 (US).

(74) Agent: KAMMERER, Patricia, A.; Arnold, White & Durkee, P.O. Box 4433, Houston, TX 77210 (US).

(81) Designated States: AT, AU, BB, BG, BR, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.

This Sheet Has Been Replaced 9608396-1

IPOS's copy

REPLACED SHEETS SG
☑ Description : paged 1 to paged 15
☑ Claim(s) : paged 16 to paged 20
☐ Drawing(s) : paged ..... to paged .....
☑ Abstract : paged ..... to paged .....
DATE OF RECEIPT .....

(54) Title: COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISEASES



(A)



(1)



(B)

(57) Abstract

The present invention provides methods for treating autoimmune disease in humans by administering to an afflicted host pharmaceutical compositions containing a therapeutically effective amount of a combination of (A) and (B) in a weight ratio ranging from about 1:1 to about 1:10 (A:B); wherein R is OH, NH_2, OW, or H; X is H, F, Cl, Br, I, OH, OW, NO_2, or NH_2; Y is H, F, Cl, Br, or I; W is (1) or a C_1 to C_{12} aliphatic group; Z is an aliphatic or aromatic group of C_1 to C_{12}; X and Y can both vary within the compound; or pharmaceutically acceptable salts thereof. Particularly disclosed herein is a composition comprising a 1 to 4 ratio of the sodium salts of phenylacetylglutamine and phenylacetic acid, formulated in both oral and parenteral forms clinically useful in the treatment of rheumatoid arthritis, lupus erythematosus, vasculitis, insulin-dependent diabetes mellitus and multiple sclerosis.